LAUSR

1090Background: CTCs play a critical role in BCa metastasis and worse prognosis even after systemic treatments such as chemotherapy and biological therapy. The mechanisms that contribute to CTCs migration and tumor aggressiveness remain unknown. Herein, we report a novel finding of the correlation between plasma IL-2 and the changes of CTC for BCa patients after therapies. Methods: Duplicate whole blood samples (7.5ml/each) were collected in EDTA tubes from 43 patients with stage III/IV BCa patients before (baseline, BL) or 3 months after (first evaluation, FE) systemic therapies respectively from patients treated at NMH. CTC enrichment and enumeration were performed in FDA approved CELLTRACKS ANALYZERII System and were linked with clinical database. The CTCs were classified as CK+, EpCAM+, DAPI+ and CD25-. ELISA for IL-2 was performed by using patients’ plasma. Kruskal-Wallis test was used for statistics. Results: CTCs were detected in 23 patients at BL and 21 patients at FE of blood draws respectively. ...